Evaluate the Quality of Life of Patients With AMD

Inclusion Criteria: \- For the 2 populations studied * Persons who have given consent to take part * Persons aged 50 years or older * Willing and able to attend all of the scheduled visits and evaluations * Macular atrophy or drusen measuring at least 125μm or multiple drusens measuring at least 63μm * Atrophic AMD diagnosed on OCT and by autofluorescence and OCT angiography by 2 independent experienced assessors * Diagnosed for less than 3 years * MAVC score ≥ 19 letters (Equivalent Snellen ≥ 20/400), by using a scale at an initial distance of 4m For patients with secondary atrophic AMD • Secondary atrophic AMD, defined by persistent atrophic AMD at 1 year after the last injection of an anti-angiogenic agent, and at least 2 years after the first injection. Exclusion Criteria: General criteria * Persons without national health insurance cover * Physical or mental disability ruling out participation * Inability to sign the written consent form, adults under guardianship * Any participation in a study involving an experimental drug during the previous 3 months (dietary supplements are authorised). * Adults under guardianship General medical history • Uncontrolled AHT Ophthalmological history * Severe non-proliferative or proliferative diabetic retinopathy * Uncontrolled glaucoma (defined as an intra-ocular pressure greater than 30mmHg despite treatment with an anti-glaucoma agent) or a history of filtration surgery * Corneal disease that could impair vision * Monogenic macular dystrophy or toxic maculopathy * History of uveitis * Amblyopia of the eye concerned * Intraocular surgery in the 3 months preceding inclusion * History of cornea transplantation in the studied eye * Treatment affecting vision: chloroquine and hydroxychloroquine, phenothiazine, tamoxifen, interferon (93), external radiotherapy of the face and neck Ophthalmological examination * Significant cataract (LOCS III grade of 5 or above, annexe 5.) (94) * Active infection in either eye * Central anterior serous or active retinopathy in either eye * Choroid neo-vascularisation * Active serous retinal detachment * Refractive error less than -15D or more than +10D